Department of Clinical Sciences and Community Health, Branch of Medical Statistics, Biometry and Epidemiology "G.A. Maccacaro," Università degli Studi di Milano, Milan, Italy.
Tish Cancer Institute, Ichan School of Medicine at Mount Sinai, New York, NY, USA.
Adv Nutr. 2021 Jul 30;12(4):1160-1176. doi: 10.1093/advances/nmaa177.
To explore the role of coffee on health outcomes in the United States, where coffee consumption is common, we conducted a meta-analysis of prospective studies investigating the magnitude (any compared with no consumption) and the dose-response shape (cups per day) of the associations between caffeinated coffee consumption and incidence/mortality of cardiovascular disease (CVD), as well as incidence of type 2 diabetes (T2D), hepatocellular carcinoma (HCC), endometrial cancer, melanoma, and nonmelanoma skin cancer. We selected the desirable health outcomes that have been shown to be positively associated with coffee consumption. Studies were identified by searching PubMed/Embase databases up to September 2019. Inclusion criteria included prospective studies that investigated the relation of ≥3 categories of caffeinated coffee consumption and the outcomes of interest. Twenty-six studies (42 distinct cohorts), with 93,706 cases/deaths and 3,713,932 participants, met the inclusion criteria. In any coffee consumers, there was a significant inverse association with the risk of CVD (RR = 0.90; 95% CI: 0.84, 0.96), T2D (RR = 0.90; 95% CI: 0.85, 0.96), endometrial cancer (RR = 0.85; 95% CI: 0.78, 0.92), melanoma (RR = 0.89; 95% CI: 0.80, 0.99), and nonmelanoma skin cancer (RR = 0.92; 95% CI: 0.89, 0.95). Coffee consumption was also inversely associated with HCC (RR = 0.93; 95% CI: 0.80, 1.08), without reaching statistical significance. The dose-response relation was nonlinear uniquely for CVD (P-nonlinearity = 0.01). In particular, the largest risk reduction was observed for 3-4 cups/d (∼120 mL/cup) and no reduction thereafter. For other outcomes, the risk decreased linearly over the whole coffee consumption range. Current patterns of consumption in the United States would account for a fraction of avoided cases/deaths ranging from 6% to 12% according to the outcome considered. This study confirms the beneficial health effects of caffeinated coffee consumption in the US population on the health outcomes considered, and quantifies their possible magnitude.
为了探索咖啡对美国健康结果的作用,因为在美国,咖啡消费很普遍,我们进行了一项荟萃分析,调查了摄入含咖啡因咖啡与心血管疾病(CVD)发病率/死亡率以及 2 型糖尿病(T2D)、肝细胞癌(HCC)、子宫内膜癌、黑色素瘤和非黑色素瘤皮肤癌发病率之间的关联的幅度(任何与不摄入相比)和剂量反应形状(杯/天)。我们选择了已显示与咖啡摄入呈正相关的理想健康结果。通过搜索 PubMed/Embase 数据库,我们确定了截至 2019 年 9 月的研究。纳入标准包括调查≥3 类含咖啡因咖啡摄入与感兴趣结局之间关系的前瞻性研究。26 项研究(42 个独立队列),共有 93706 例/死亡和 3713932 名参与者符合纳入标准。在任何咖啡消费者中,与 CVD(RR=0.90;95%CI:0.84,0.96)、T2D(RR=0.90;95%CI:0.85,0.96)、子宫内膜癌(RR=0.85;95%CI:0.78,0.92)、黑色素瘤(RR=0.89;95%CI:0.80,0.99)和非黑色素瘤皮肤癌(RR=0.92;95%CI:0.89,0.95)的风险呈显著负相关。咖啡摄入也与 HCC(RR=0.93;95%CI:0.80,1.08)呈负相关,但无统计学意义。剂量-反应关系仅对 CVD 呈非线性(P-非线性=0.01)。特别是,观察到 3-4 杯/天(约 120 毫升/杯)的最大风险降低,此后无降低。对于其他结局,风险在整个咖啡摄入范围内呈线性下降。根据所考虑的结局,美国目前的消费模式将占避免病例/死亡的比例从 6%到 12%不等。本研究证实了美国人群中含咖啡因咖啡消费对所考虑的健康结果的有益健康影响,并量化了它们可能的幅度。